

1986 No. 2331

DANGEROUS DRUGS

The Misuse of Drugs (Designation) Order 1986

<i>Made - - - -</i>	<i>22nd December 1986</i>
<i>Laid before Parliament</i>	<i>13th January 1987</i>
<i>Coming into Operation</i>	<i>1st April 1987</i>

In pursuance of section 7(4) and (5) of the Misuse of Drugs Act 1971(a), on the recommendation of the Advisory Council on the Misuse of Drugs, I hereby make the following Order:—

1. This Order may be cited as the Misuse of Drugs (Designation) Order 1986 and shall come into operation on 1st April 1987.

2.—(1) The controlled drugs specified in Part I of the Schedule hereto are hereby designated as drugs to which section 7(4) of the Misuse of Drugs Act 1971 applies.

(2) Part II of the Schedule hereto shall have effect for the purpose of specifying those controlled drugs which are excepted from Part I thereof.

3. The Misuse of Drugs (Designation) Order 1977(b) and the Misuse of Drugs (Designation) (Variation) Order 1984(c) are hereby revoked.

Douglas Hurd,
One of Her Majesty's Principal
Secretaries of State.

Home Office.
22nd December 1986.

SCHEDULE

Article 2

PART I

CONTROLLED DRUGS TO WHICH SECTION 7(4) OF THE MISUSE OF DRUGS ACT 1971 APPLIES

1. The following substances and products, namely:—

- | | | |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (a) | Bufotenine
Cannabinol
Cannabinol derivatives
Cannabis
Cannabis resin
Cathinone
Coca leaf
Concentrate of poppy-straw
Eticyclidine
Lysergamide | Lysergide and other <i>N</i> -alkyl derivatives of lysergamide
Mescaline
Psilocin
Raw opium
Rolicyclidine
Tenocyclidine
4-Bromo-2, 5-dimethoxy- α -methylphenethylamine
<i>N</i> , <i>N</i> -Diethyltryptamine
<i>N</i> , <i>N</i> -Dimethyltryptamine
2,5-Dimethoxy- α , 4-dimethylphenethylamine |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
- (b) any compound (not being a compound for the time being specified in subparagraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by substitution at the nitrogen atom of the sidechain with one or more alkyl substituents but no other substituent;
- (c) any compound (not being methoxyphenamine or a compound for the time being specified in subparagraph (a) above) structurally derived from phenethylamine, an *N*-alkylphenethylamine, α -methylphenethylamine, an *N*-alkyl- α -methylphenethylamine, α -ethylphenethylamine, or an *N*-alkyl- α -ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylendioxy or halide substituents, whether or not further substituted in the ring by one or more other univalent substituents;
- (d) any compound (not being a compound for the time being specified in Part II of this Schedule) structurally derived from fentanyl by modification in any of the following ways, that is to say,
- (i) by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;
 - (ii) by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;
 - (iii) by substitution in the piperidine ring with alkyl or alkenyl groups;
 - (iv) by substitution in the aniline ring with alkyl, alkoxy, alkylendioxy, halogeno or haloalkyl groups;
 - (v) by substitution at the 4-position of the piperidine ring with any alkoxycarbonyl or alkoxyalkyl or acyloxy group;
 - (vi) by replacement of the *N*-propionyl group by another acyl group;
- (e) any compound (not being a compound for the time being specified in Part II of this Schedule) that is structurally derived from pethidine by modification in any of the following ways, that is to say,
- (i) by replacement of the 1-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted;
 - (ii) by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;
 - (iii) by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups;

- (iv) by replacement of the 4-ethoxycarbonyl by any other alkoxycarbonyl or any alkoxyalkyl or acyloxy group;
 - (v) by formation of an *N*-oxide or of a quaternary base.
2. Any stereoisomeric form of a substance specified in paragraph 1 above.
 3. Any ester or ether of a substance specified in paragraph 1 or 2 above.
 4. Any salt of a substance specified in any of paragraphs 1 to 3 above.
 5. Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4 above.

PART II

CONTROLLED DRUGS EXCEPTED FROM PART I

1. The compounds referred to in paragraph 1(*d*) of Part I of this Schedule are—
 - Alfentanil
 - Carfentanil
 - Lofentanil
 - Sufentanil.
2. The compounds referred to in paragraph 1(*e*) of Part I of this Schedule are—
 - Allyprodine
 - Alphameprodine
 - Alphaprodine
 - Anileridine
 - Betameprodine
 - Betaprodine
 - Hydroxypethidine
 - Properidine
 - Trimeperidine.

EXPLANATORY NOTE

(This Note is not part of the Order.)

Section 7(3) of the Misuse of Drugs Act 1971 requires regulations to be made to allow the use for medical purposes of the drugs which are subject to control under the Act. Section 7(3) does not however apply to any drug designated by order under section 7(4) as a drug to which section 7(4) is to apply. This Order, which replaces the Misuse of Drugs (Designation) Order 1977, as amended, designates for this purpose the drugs specified in Part I of the Schedule to the Order. It differs from the previous Order by the addition, in paragraph 1 of Part I, of Cathinone in sub-paragraph (*a*) and two new sub-paragraphs (*d*) and (*e*), which relate, respectively, to certain fentanyl derivatives and certain pethidine derivatives.

Part II of the Schedule specifies certain compounds which are excepted from paragraph 1(*d*) and (*e*) of Part I and are therefore not designated by this Order.